As of December 31, 2024, the Company’s
subsidiaries are as follows:
| Subsidiaries | | Date of
incorporation | | Place of
incorporation | | Ownership | | Principal activities | | Health Ever Biotech Co., Ltd. (“HEB”) | | August 1, 2002 | | Taiwan | | 100% owned by the Company | | Research, development, manufacturing | | | | | | | | | | | | Genvace Biotechnology (“GB”) | | September 14, 2021 | | Taiwan | | 100% owned by HEB | | Research and development | | | | | | | | | | | | Top ShunXing Bio-Tech Co., (“TSB”) | | March 4, 2019 | | Hong Kong | | 100% owned by the Company | | Investment holding | | | | | | | | | | | | Innovative Biotech Co., (“IB”) | | July 1, 2019 | | People’s Republic of China (“China”) | | 100% owned by TSB | | Research, development, manufacturing | | | | | | | | | | | | Jyong Biotech International Pte. Ltd. | | September 29, 2022 | | Singapore | | 100% owned by the Company | | Leasing of non-financial intangible assets |
|